

036

PATENT
Attorney Docket No. 4779US

Box 50

CERTIFICATE OF MAILING (under 37 C.F.R. § 1.10 if checked)

I hereby certify that this transmittal along with all items checked below is being deposited with the United States Postal Service

as first class mail, postage prepaid (37 C.F.R. § 1.8)
 "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10
 Express mail label mailing number:

K
 AUG 10 2001
 OIPE
 PATENT & TRADEMARK OFFICE
 Lynette Eliason
 Typed name of person mailing transmittal

July 19, 2001
 Date of Deposit

Lynette Eliason
 Signature of person mailing transmittal

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:	To be assigned	Group Art Unit No.:	1645
Applicant(s):	Steidler et al.	Filing date:	April 19, 2001
Serial No.:	09/838,718	For (title):	USE OF A CYTOKINE-PRODUCING LACTOCOCCUS STRAIN TO TREAT COLITIS

COMMUNICATION TRANSMITTAL

Commissioner for Patents
 Washington, D.C. 20231

Sir:

Enclosed for filing in connection with the above-identified patent application, and submitted in the order listed, are:

Postcard receipt acknowledgment (attached to the front of this transmittal).
 Duplicate copy of this transmittal sheet in the event that additional filing fees are required under 37 C.F.R. § 1.16. Any such fees may be charged to deposit account no. 20-1469.
 Check no. in the amount of \$ for the presentation of extra claims as calculated in the remarks section below.
 Preliminary amendment.
 Amendment or other communication in response to the non-final office action mailed.
 Amendment or other communication under 37 C.F.R. § 1.116 in response to the final office action mailed.
 Petition for Extension of Time in duplicate with check no. in the amount of \$.
 Verified statement(s) to establish small entity status under 37 C.F.R. § 1.9 and 37 C.F.R. § 1.27 signed by (or on behalf of).
 Information disclosure statement and information disclosure citation form PTO-1449 with copies of listed documents.
 Response to notice to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures.

Remarks:


An amendment has been made involving one or more claims in the application. The calculation to determine whether any additional fee is due is presented below.

1	2	3	\$EXTRA
Total claims	-	=	x 18.00 =
Indep. claims	-	=	x 78.00 =
First presentation of a multiple dep. claim (+260.00)			
SUBTOTAL			
Reduction for small entity - 50% of subtotal*			
TOTAL ADDITIONAL FEE (subtotal minus any reduction)			

*Verified statement(s) must be attached to support this reduction if small entity status has not been previously established.

- 1 Claims remaining after amendment.
- 2 Highest number of claims previously paid for. Not less than 20 for total claims and 3 for independent claims.
- 3 Difference between claims remaining and highest number previously paid for. If less than zero, enter "0."

The commissioner is authorized to charge any additional fees required but not submitted with any document or request requiring fee payment under 37 C.F.R. §§ 1.16 and 1.17 to deposit account no. 20-1469 during the entire pendency of this application.

Respectfully submitted,


Allen C. Turner
 Reg. No. 33,941
 TRASKBRITT
 P.O. Box 2550
 Salt Lake City, UT 84110-2550
 (801) 532-1922

Date: July 19, 2001
 Enclosures: As identified above



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/838,718	04/19/2001	Lothar Steidler	4779US

CONFIRMATION NO. 3041

24247
TRASK BRITT
P.O. BOX 2550
SALT LAKE CITY, UT 84110

FORMALITIES LETTER



OC00000006197998

Date Mailed: 06/19/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at
patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE